CDPQ acquires stake in Sebia

CDPQ, whose assets total C$270bn, said the stake was „significant“.

Headquartered in Lisses (near Paris, France), Sebia Group is a is the world’s leading provider of clinical protein electrophoresis equipment and reagents. The company’s technology primarily is used to screen and monitor protein biomarkers for multiple myeloma, diabetes and hemoglobinopathies as well as rare diseases. Sebia said it wants to expand particularly its diabetes franchise and seek for novel applications of its technology.

Benoît Adelus, CEO of Sebia said: "Over the last years, Sebia has kept upgrading its technology and successfully applying it to attractive niche markets where it provides clear medical benefits. Having CDPQ as a long-term partner to the company will contribute to our development in line with this strategy."

"The accuracy, efficiency and speed of Sebia's tests, coupled with its proven technology, make them critical to the global medical community," said Stéphane Etroy, Executive Vice-President and Head of Private Equity at CDPQ. "The company's rapid growth and development into adjacent therapeutics areas is evidence not only of the strength of its management team, but also of its resilient business model. We will work with our partners to support the company as it expands into new opportunities in the diagnostics sector."